After reanalyzing data from its halted 1999 phase III trial, Immune Response (Carlsbad, CA) claims its experimental AIDS vaccine Remune is effective. The firm's share price rose 58% to $2.58 on the announcement, which was published in the April issue of HIV Medicine (2, 68–77, 2001). The company says viral load was measured more frequently in a subset of 252 patients than in the original 2,527-patient study, allowing researchers to find immunization that wasn't apparent from analysis of the whole group. But lead researcher Joseph Kahn (University of California San Francisco; UCSF) says the new analysis of the study “is data-dredging. It's looking at information a number of ways until you find what you are looking for and reporting it as 'Eureka.' That's not science. That's marketing.” Last September, Immune Response began legal proceedings against Kahn and co-researcher Stephen Lagakos (Harvard University, Cambridge, MA) for suppressing the subset data from their manuscript submission to JAMA (Nat. Biotechnol. 18, 1235, 2000). UCSF officials say the researchers and the firm agreed to seek binding arbitration in order to settle the disagreement.